Mutant-selective EGFR inhibitors and uses thereof
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
1. A method for selectively inhibiting at least one mutant of epidermal growth factor receptor (EGFR) as compared to wild-type epidermal growth factor receptor (WT EGFR), in a biological sample or in a patient, comprising contacting the biological sample with, or administering to the patient, a compound of formula I, or a composition thereof:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is —CF 3 or —Cl;
W is —O— or —NH—;
R 2 is —R or
R 3 is —R, —C(O)R, or —C(O)OR; and
each R is independently C 1-4 alkyl or C 1-4 fluoroalkyl.
2. The method according to claim 1 , wherein said compound is sparing for WT EGFR.
3. The method according to claim 1 , wherein the at least one mutant is T790M.
4. The method according to claim 2 , wherein the at least one mutant is T790M.
5. The method according to claim 1 , wherein the at least one mutant of EGFR is an activating mutant.
6. The method according to claim 5 , wherein the at least one activating mutant of EGFR is a deletion mutant.
7. The method according to claim 5 , wherein the at least one activating mutant of EGFR is a point mutation.
8. The method according to claim 6 , wherein the at least one activating mutant is delE746-A750.
9. The method according to claim 7 wherein the at least one activating mutant is L858R.
10. The method according to claim 7 , wherein the at least one activating mutant is G719S.
11. The method according to claim 1 , wherein the compound selectively inhibits at least one activating mutant and T790M.
12. The method according to claim 11 , wherein the at least one activating mutant of EGFR is a deletion mutant.
13. The method according to claim 11 , wherein the at least one mutant of EGFR is a point mutation.
14. The method according to claim 12 , wherein the at least one activating mutant is delE746-A750.
15. The method according to claim 13 , wherein the at least one activating mutant is L858R.
16. The method according to claim 13 , wherein the at least one activating mutant is G719S.
17. The method according to claim 5 , wherein the compound is sparing for WT EGFR.
18. A method for modulating mutant epidermal growth factor receptor (EGFR) in a patient, comprising administering to the patient a composition comprising a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is —CF 3 or —Cl;
W is —O— or —NH—;
R 2 is —R or
R 3 is —R, —C(O)R, or —C(O)OR; and
each R is independently C 1-4 alkyl or C 1-4 fluoroalkyl.
19. The method according to claim 18 , wherein the patient is suffering from a cancer.
20. The method according to claim 19 , wherein the cancer is non-small cell lung cancer.
21. The method according to claim 3 , wherein the compound further selectively inhibits at least one activating mutant.
22. The method according to claim 1 , wherein R 1 is —CF 3 .
23. The method according to claim 1 , wherein R 1 is —Cl.
24. The method according to claim 1 , wherein R 2 is
25. The method according to claim 1 , wherein the compound of formula I has the structure:
or a pharmaceutically acceptable salt thereof.
26. The method according to claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.